In this study we used cellular magnetic resonance imaging (MRI) to detect mesenchymal stem cells (MSC) labeled with a Fluorine-19 (19F) agent. 19F-MRI offers unambiguous detection and in vivo quantification of labeled cells. We investigated two common stem cell transplant mouse models: an immune competent, syngeneic transplant model and an immune compromised, xenograft transplant model. 19F labelled stem cells were implanted intramuscularly into the hindlimb of healthy mice. The transplant was then monitored for up to 17 days using 19F-MRI, after which the tissue was excised for fluorescence microscopy and immunohistochemisty. Immediately following transplantation, 19F-MRI quantification correlated very well with the expected cell number in both models. The 19F signal decreased over time in both models, with a more rapid decrease in the syngeneic model. By endpoint, only 2/7 syngeneic mice had any detectable 19F signal. In the xenograft model, all mice had detectable signal at endpoint. Fluorescence microscopy and immunohistochemistry were used to show that the 19F signal was related to the presence of bystander labeled macrophages, and not original MSC. Our results show that 19F-MRI is an excellent tool for verifying the delivery of therapeutic cells early after transplantation. However, in certain circumstances the transfer of cellular label to other bystander cells may confuse interpretation of the long-term fate of the transplanted cells.
Objectives: The current lack of efficacy for any chemo- or molecular therapeutic in the treatment of brain metastases is thought to be due, in part, to the heterogeneous permeability of the blood-brain-barrier (BBB). Little is known about how heterogeneous permeability develops, or how it varies among individual metastases. Understanding the BBB's role in metastasis will be crucial to the development of new, more effective therapies. In this article, we developed the first magnetic resonance imaging-based strategy to detect and measure the volumes of BBB permeable and nonpermeable metastases and studied the development of altered BBB permeability in metastases in vivo, over time in a mouse model of breast cancer metastasis to the brain. Materials and Methods: Animals bearing human experimental brain metastases of breast cancer (231-BR cells) were imaged, using 3-dimensional balanced steady-state free precession to visualize total metastases, and contrast-enhanced T1-weighted spin echo with gadopentetic acid (Gd-DTPA) to visualize which of these displayed contrast enhancement, as Gd-DTPA leakage is indicative of altered BBB permeability. Results: Metastases detected 20 days after injection showed no Gd-DTPA enhancement. At day 25, 6.1% ± 6.3% (mean ± standard deviation) of metastases enhanced, and by day 30, 28.1% ± 14.2% enhanced (P < 0.05). Enhancing metastases (mid: 0.14 ± 0.18 mm3, late: 0.24 ± 0.32 mm3) had larger volumes than nonenhancing (mid: 0.04 ± 0.04 mm3, late: 0.09 ± 0.09 mm3, P < 0.05); however, there was no significant difference between the growth rates of the 2. Conclusions: A significant number of brain metastases were uniformly nonpermeable, which highlights the need for developing treatment strategies that can overcome the permeability of the BBB. The model developed herein can provide the basis for in vivo evaluation of both BBB permeable and nonpermeable metastases response to therapy.
Purpose: To examine the ability of TrueFISP imaging for evaluating tumor size in mouse brain at high field.Materials and Methods: Brains of healthy and glioma‐implanted nude mice were imaged at 4.7T and 9.4T. 3D imaging was performed with TrueFISP and T2w‐RARE. Radiofrequency pulses with alternating phase and the sum‐of‐squares reconstruction method were used in TrueFISP imaging. The contrast‐to‐noise ratio (CNR) was evaluated in healthy and in tumoral brain regions.Results: Banding artifact was correctly suppressed in TrueFISP images thanks to the method used. The signal‐to‐noise ratio (SNR) and CNR were comparable in TrueFISP and T2w‐RARE images at 4.7T, but acquisition was around 4 times shorter with TrueFISP. Tumor was well detected at 4.7T with TrueFISP, but CNR between tumor and healthy tissue was low at 9.4T.Conclusion: TrueFISP is efficient and fast to perform brain imaging at 4.7T. Multiple TrueFISP acquisitions with phase‐cycled radiofrequency (RF) pulses and sum‐of‐squares reconstruction allow suppression of banding artifact. Tumoral regions were well detected and the method allows longitudinal studies of tumor growth. J. Magn. Reson. Imaging 2008;28:497–503.